NASDAQ
7.14USD
+5.71 (+399.30%)
We have scored 4 news catalysts on Aethlon Medical, Inc. (AEMD) over the past 12 months. The biggest single-day move next to one of them came Sep 17, 2026, when AEMD closed +388.8%: “BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruger & Company, Inc. (NYSE – RGR), Atkore, Inc. (NYSE – ATKR), Centerspace (NYSE – CSR), Aethlon Medical, Inc. (Nasdaq – AEMD)”. Coverage across the window leans negative (average ticker sentiment −0.15). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.8M
P/E
—
EPS
—
Beta
1.40
52W range
1.41-41.5
Day range
6.60–9.50
Open
8.54
Prev close
1.43
Volume
79.5M
Avg volume
820.4K
Dividend
0.00
IPO
1999-03-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Aethlon Medical, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AEMD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
